SCHEMBL7096192

SCHEMBL7096192

NS(=O)(=O)n1cnc2c(Oc3ccccc3)nc3ccccc3c21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
HTT P42858 1/20 0.40
ABCG2 Q9UNQ0 1/20 0.40
MAPT P10636 3/20 0.39
KDM4E B2RXH2 2/20 0.39
GLA P06280 1/20 0.39
KMT2A Q03164 1/20 0.39
ALDH1A1 P00352 2/20 0.39
POLB P06746 2/20 0.39
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA9 Q16790 2/20 0.38
HPGD P15428 1/20 0.38
CA12 O43570 1/20 0.38
RAB9A P51151 1/20 0.38
ELANE P08246 1/20 0.37
HRH4 Q9H3N8 2/20 0.36
HRH2 P25021 1/20 0.36
ADRA1D P25100 1/20 0.36
HTR2A P28223 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7102791 0.80 TLR7 (0.54) LMNAPOLBHRH2ADRA1DHTR2A
SCHEMBL6107082 0.79 HTT (0.44) LMNAHTTABCG2MAPTKDM4E
SCHEMBL6106127 0.79 HTT (0.44) LMNAHTTABCG2MAPTKDM4E
SCHEMBL6094441 0.74 CA1 (0.40) KMT2AALDH1A1CA1CA2CA9
SCHEMBL6702926 0.73 TLR7 (0.44) LMNAHTTABCG2MAPTKDM4E
SCHEMBL5136202 0.69 TLR7 (0.55) LMNAPOLBHRH2ADRA1DHTR2A
SCHEMBL6701754 0.69 LMNA (0.39) LMNAHTTABCG2POLBHPGD
SCHEMBL6928736 0.69 ACP1 (0.42) LMNAHTTMAPTPOLBHRH4
SCHEMBL3813757 0.69 ERN1 (0.41) LMNAHTTKDM4EKMT2AALDH1A1
SCHEMBL6700062 0.68 LMNA (0.38) LMNAHTTABCG2MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1343783-A2 SUBSTITUTED IMIDAZOPYRIDINES 3M Innovative Properties Company (US) 2003-09-17 EP disclosed
US-20020107262-A1 SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY 2002-08-08 US disclosed
WO-2002046194-A2 SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107262-A1 SUBSTITUTED IMIDAZOPYRIDINES IRF3, IFNG, EIF2AK2 LMNA 4502/4885HTT 4635/4885ABCG2 4609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.